Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
47.09
Nov 19 • 3:59 PM ET Dollar change-1.60 Percentage change(-3.29%)
Aftermarket Close
47.09
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
1.97B
Enterprise Value
1.69B
Income
-166.99M
Sales
621.70M
Book/sh
33.46
Cash/sh
7.97
Employees
3000
IPO
Feb 02, 1995
P/E
-
Forward P/E
52.91
PEG
2.18
P/S
3.16
P/B
1.41
P/C
5.91
P/FCF
71.69
EV/EBITDA
39.78
EV/Sales
2.71
Quick Ratio
2.34
Current Ratio
2.68
Debt/Eq
0.04
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-3.62
EPS next Y
0.89
EPS next Q
0.11
EPS this Y
18.75%
EPS next Y
56.14%
EPS next 5Y
24.22%
EPS past 3/5Y
-158.10% -
Sales past 3/5Y
-2.22% 3.89%
EPS Y/Y TTM
-196.27%
Sales Y/Y TTM
4.65%
EPS Q/Q
-85.82%
Sales Q/Q
4.96%
Insider Own
1.58%
Insider Trans
1.60%
Inst Own
110.51%
Inst Trans
-6.63%
ROA
-8.38%
ROE
-10.11%
ROIC
-11.52%
Gross Margin
44.23%
Oper. Margin
-2.27%
Profit Margin
-26.86%
SMA20
13.37%
SMA50
24.43%
SMA200
64.36%
Trades
Shs Outstand
41.76M
Shs Float
41.10M
52W High
50.06 -5.92%
52W Low
15.93 195.61%
Volatility
6.64% 6.33%
ATR (14)
2.94
RSI (14)
60.85
Beta
1.35
Rel Volume
1.33
Avg Volume
1.03M
Volume
1,368,235
Perf Week
7.36%
Perf Month
28.10%
Perf Quarter
25.91%
Perf Half Y
140.99%
Perf YTD
41.58%
Perf Year
56.81%
Perf 3Y
-14.63%
Perf 5Y
-60.60%
Perf 10Y
193.40%
Prev Close
48.69
Price
47.09
Change %
-3.29%
Consensus
Buy
Avg. Price Target
$52.60
Implied Upside
+11.7%
Analysts7incl. previous ratings
Rating Distribution5 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 05, 2026Upgrade
EVR logoEEvercore ISI
In-line → Outperform$50+6.2%
Dec 19, 2025Reiterated
NNeedham
Buy$42 → $44-6.6%
Oct 30, 2025Upgrade
JEF logoJJefferies
Hold → Buy$38-19.3%
Aug 06, 2025Upgrade
RJF logoRRaymond James
Mkt Perform → Outperform$35-25.7%
Jul 22, 2025Resumed
SStephens
Equal-Weight$35-25.7%
Dec 18, 2024Upgrade
SStephens
Equal-Weight → Overweight$50 → $60+27.4%
Apr 04, 2024Initiated
JEF logoJJefferies
Hold$64+35.9%
Feb 01, 2024Reiterated
RILY logoRB. Riley Securities
Buy$61 → $79+67.8%
Jul 19, 2023Initiated
RJF logoRRaymond James
Mkt Perform
May 10, 2023Downgrade
KEY logoKKeyBanc Capital Markets
Overweight → Sector Weight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Starr EphraimSVP, Gen Counsel & SecretaryJul 31 '26Buy24.173358,09668,728Aug 04 06:11 PM
Cornog William LDirectorMay 18 '26Buy16.3810,000163,80019,703May 19 04:10 PM
Azenta, Inc. is a global provider of life sciences solutions, enabling organizations worldwide to bring impactful breakthroughs and therapies to market faster. The company offers a suite of reliable cold-chain sample management solutions and multiomics services supporting drug development, clinical research, and advanced cell therapies for pharmaceutical, biotechnology, academic, and healthcare institutions globally. It operates through the following segments: Sample Management Solutions and Multiomics. The Sample Management Solutions segment provides end-to-end sample management products and services, including Sample Repository Services (SRS). Its core products include automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled-rate thawing devices. The Multiomics segment delivers genomic and other sample analysis services, including gene sequencing, gene synthesis, and related services. The company was founded in 1978 and is headquartered in Burlington, MA.
Ph.D.Dr. Martin D. Madaus D.V.M.
Executive VP & CFOMr. Lawrence Y. Lin
Senior VPMr. Ephraim Starr
Senior VP & Chief HR OfficerMs. Olga Pirogova
AdvisorDr. Ginger Zhou Ph.D.